N/A
Completed N=676
To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension
Source: ClinicalTrials.gov NCT03021265 ↗Enrolled (actual)
676
Serious AEs
3.0%
Results posted
May 2020
Primary outcomePrimary: Frequency of Patients With Any Suspected Adverse Drug Reactions — 32 Participants
Summary
Study to evaluate real-world safety, effectiveness and appropriate use of Micatrio® Combination Tablets treatment in patients with hypertension
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Frequency of Patients With Any Suspected Adverse Drug Reactions |
32 | — |
| SECONDARY Change From Baseline in Clinic Diastolic Blood Pressure at Week 52 |
-2.0 | — |
| SECONDARY Change From Baseline in Clinic Systolic Blood Pressure at Week 52 |
-2.6 | — |
Eligibility Criteria
Inclusion criteria
- Patients who are prescribed with Micatrio® Combination Tablets by the discretion of investigators based on the Japanese package insert
- Patients who have never been treated with Micatrio® Combination Tablets before enrolment
Exclusion criteria
Patients who are participating/planned to participate in a clinical trial
Data sourced from ClinicalTrials.gov (NCT03021265). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.